Stacie Jones
Concepts (413)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Food Hypersensitivity | 43 | 2024 | 99 | 11.110 |
Why?
| Peanut Hypersensitivity | 48 | 2024 | 90 | 9.140 |
Why?
| Desensitization, Immunologic | 45 | 2024 | 108 | 8.740 |
Why?
| Allergens | 51 | 2024 | 147 | 7.200 |
Why?
| Egg Hypersensitivity | 16 | 2021 | 26 | 2.610 |
Why?
| Anaphylaxis | 15 | 2024 | 72 | 2.390 |
Why?
| Immunoglobulin E | 29 | 2024 | 94 | 2.220 |
Why?
| Administration, Oral | 35 | 2023 | 461 | 1.790 |
Why?
| Asthma | 11 | 2019 | 293 | 1.790 |
Why?
| Child | 75 | 2024 | 7372 | 1.760 |
Why?
| Immune Tolerance | 16 | 2022 | 105 | 1.750 |
Why?
| Child, Preschool | 57 | 2024 | 4161 | 1.700 |
Why?
| Hypersensitivity | 4 | 2023 | 83 | 1.560 |
Why?
| Food Supply | 2 | 2023 | 101 | 1.490 |
Why?
| Immunotherapy | 10 | 2024 | 264 | 1.400 |
Why?
| Humans | 134 | 2024 | 54304 | 1.240 |
Why?
| Adolescent | 47 | 2024 | 6896 | 1.230 |
Why?
| Epinephrine | 10 | 2022 | 97 | 1.120 |
Why?
| Eosinophilic Esophagitis | 4 | 2019 | 33 | 1.090 |
Why?
| Double-Blind Method | 18 | 2023 | 742 | 1.000 |
Why?
| Nuts | 3 | 2022 | 10 | 0.950 |
Why?
| Patient Advocacy | 2 | 2013 | 23 | 0.900 |
Why?
| Skin Tests | 17 | 2019 | 58 | 0.900 |
Why?
| Male | 65 | 2024 | 27335 | 0.840 |
Why?
| Eosinophils | 3 | 2018 | 36 | 0.820 |
Why?
| Infant | 35 | 2024 | 3832 | 0.800 |
Why?
| Health Education | 2 | 2013 | 177 | 0.800 |
Why?
| Allergy and Immunology | 3 | 2018 | 15 | 0.790 |
Why?
| Female | 64 | 2024 | 28457 | 0.790 |
Why?
| Patient Education as Topic | 3 | 2017 | 310 | 0.770 |
Why?
| Transdermal Patch | 2 | 2019 | 3 | 0.760 |
Why?
| Esophagus | 2 | 2018 | 81 | 0.740 |
Why?
| Milk Hypersensitivity | 6 | 2024 | 18 | 0.700 |
Why?
| School Nursing | 2 | 2010 | 13 | 0.660 |
Why?
| Arkansas | 13 | 2019 | 2097 | 0.610 |
Why?
| Egg Proteins | 6 | 2019 | 19 | 0.610 |
Why?
| Immunoglobulin G | 13 | 2022 | 227 | 0.590 |
Why?
| Treatment Outcome | 20 | 2022 | 5609 | 0.580 |
Why?
| Health Literacy | 1 | 2019 | 137 | 0.570 |
Why?
| T-Lymphocytes, Regulatory | 5 | 2022 | 85 | 0.560 |
Why?
| Sinusitis | 2 | 2007 | 60 | 0.550 |
Why?
| National Institute of Allergy and Infectious Diseases (U.S.) | 12 | 2018 | 15 | 0.540 |
Why?
| Plant Proteins | 6 | 2018 | 73 | 0.500 |
Why?
| Environmental Exposure | 4 | 2017 | 205 | 0.500 |
Why?
| Rural Population | 3 | 2018 | 597 | 0.470 |
Why?
| Adult | 24 | 2024 | 14189 | 0.460 |
Why?
| Follow-Up Studies | 11 | 2021 | 2389 | 0.460 |
Why?
| Risk Factors | 13 | 2019 | 3934 | 0.450 |
Why?
| Basophils | 5 | 2018 | 17 | 0.440 |
Why?
| Receptors, Adrenergic, beta-2 | 4 | 2012 | 17 | 0.440 |
Why?
| Practice Guidelines as Topic | 6 | 2017 | 487 | 0.440 |
Why?
| Prevalence | 9 | 2019 | 1026 | 0.430 |
Why?
| Poverty | 2 | 2012 | 231 | 0.430 |
Why?
| Administration, Cutaneous | 5 | 2023 | 63 | 0.410 |
Why?
| Young Adult | 15 | 2024 | 4313 | 0.400 |
Why?
| Gastrointestinal Tract | 2 | 2011 | 134 | 0.400 |
Why?
| Dermatitis, Atopic | 7 | 2016 | 92 | 0.390 |
Why?
| Family | 1 | 2011 | 190 | 0.370 |
Why?
| Education, Nursing, Continuing | 1 | 2010 | 24 | 0.370 |
Why?
| Parents | 2 | 2011 | 343 | 0.370 |
Why?
| Cross-Sectional Studies | 6 | 2019 | 1693 | 0.360 |
Why?
| Nurse's Role | 1 | 2010 | 90 | 0.360 |
Why?
| Cytokines | 6 | 2021 | 677 | 0.360 |
Why?
| Urban Population | 2 | 2010 | 182 | 0.340 |
Why?
| Antibodies, Monoclonal | 2 | 2011 | 564 | 0.340 |
Why?
| Mouth | 1 | 2009 | 35 | 0.340 |
Why?
| Clinical Competence | 3 | 2013 | 444 | 0.330 |
Why?
| Biomedical Research | 2 | 2018 | 235 | 0.330 |
Why?
| United States | 21 | 2018 | 5204 | 0.320 |
Why?
| Air Pollution, Indoor | 1 | 2008 | 28 | 0.320 |
Why?
| Epidermal Growth Factor | 2 | 2005 | 38 | 0.320 |
Why?
| Rural Health | 1 | 2008 | 102 | 0.320 |
Why?
| Epitopes | 4 | 2022 | 89 | 0.320 |
Why?
| Lung | 3 | 2019 | 507 | 0.320 |
Why?
| Sympathomimetics | 3 | 2016 | 18 | 0.310 |
Why?
| Adrenergic beta-Agonists | 3 | 2015 | 43 | 0.300 |
Why?
| CD4-Positive T-Lymphocytes | 2 | 2019 | 181 | 0.290 |
Why?
| Immunologic Factors | 3 | 2022 | 130 | 0.280 |
Why?
| Anti-Infective Agents | 1 | 2007 | 111 | 0.280 |
Why?
| Case Management | 1 | 2006 | 45 | 0.280 |
Why?
| Wound Healing | 2 | 2005 | 228 | 0.280 |
Why?
| Immunization | 5 | 2019 | 95 | 0.280 |
Why?
| Phenotype | 3 | 2018 | 820 | 0.280 |
Why?
| Cost of Illness | 1 | 2006 | 132 | 0.270 |
Why?
| Anti-Allergic Agents | 2 | 2024 | 16 | 0.270 |
Why?
| Health Knowledge, Attitudes, Practice | 1 | 2010 | 538 | 0.270 |
Why?
| Population Surveillance | 1 | 2006 | 183 | 0.260 |
Why?
| Fear | 1 | 2006 | 87 | 0.260 |
Why?
| Administration, Sublingual | 4 | 2014 | 18 | 0.260 |
Why?
| Animals | 15 | 2024 | 14402 | 0.260 |
Why?
| Life Style | 1 | 2006 | 155 | 0.260 |
Why?
| Mycoses | 1 | 2006 | 162 | 0.250 |
Why?
| Prospective Studies | 7 | 2020 | 2604 | 0.250 |
Why?
| Nutritional Status | 2 | 2023 | 153 | 0.240 |
Why?
| Body Mass Index | 1 | 2007 | 705 | 0.240 |
Why?
| Severity of Illness Index | 5 | 2012 | 1083 | 0.240 |
Why?
| Quality of Life | 2 | 2021 | 922 | 0.240 |
Why?
| Medicine, Chinese Traditional | 2 | 2015 | 8 | 0.230 |
Why?
| Agricultural Workers' Diseases | 1 | 2003 | 7 | 0.230 |
Why?
| Dietetics | 3 | 2017 | 13 | 0.230 |
Why?
| Cell Movement | 1 | 2004 | 271 | 0.230 |
Why?
| Aircraft | 1 | 2003 | 12 | 0.230 |
Why?
| Leukocytes, Mononuclear | 4 | 2017 | 133 | 0.230 |
Why?
| Pesticides | 1 | 2003 | 22 | 0.230 |
Why?
| Candy | 1 | 2002 | 3 | 0.230 |
Why?
| Age Factors | 4 | 2020 | 1200 | 0.220 |
Why?
| Apoptosis | 1 | 2009 | 1302 | 0.220 |
Why?
| Antifungal Agents | 1 | 2006 | 363 | 0.220 |
Why?
| T-Lymphocyte Subsets | 2 | 2023 | 41 | 0.210 |
Why?
| Spirometry | 2 | 2018 | 30 | 0.210 |
Why?
| Th2 Cells | 2 | 2022 | 26 | 0.210 |
Why?
| Dust | 2 | 2014 | 24 | 0.210 |
Why?
| Antigens, Plant | 3 | 2020 | 15 | 0.210 |
Why?
| Diet | 2 | 2017 | 584 | 0.200 |
Why?
| Respiratory Hypersensitivity | 2 | 2019 | 18 | 0.200 |
Why?
| Toll-Like Receptor 8 | 1 | 2021 | 3 | 0.200 |
Why?
| Carbachol | 2 | 2019 | 33 | 0.200 |
Why?
| Occupational Exposure | 1 | 2003 | 129 | 0.200 |
Why?
| Mosaicism | 1 | 2021 | 18 | 0.200 |
Why?
| Immunologic Deficiency Syndromes | 1 | 2021 | 21 | 0.200 |
Why?
| Longitudinal Studies | 3 | 2023 | 742 | 0.200 |
Why?
| Middle Aged | 11 | 2024 | 13076 | 0.200 |
Why?
| Pancytopenia | 1 | 2021 | 40 | 0.190 |
Why?
| T-Lymphocytes | 3 | 2021 | 374 | 0.190 |
Why?
| Health Promotion | 1 | 2023 | 297 | 0.190 |
Why?
| Clinical Trials as Topic | 3 | 2022 | 490 | 0.190 |
Why?
| Immunity, Mucosal | 2 | 2010 | 20 | 0.180 |
Why?
| Bronchodilator Agents | 2 | 2019 | 74 | 0.180 |
Why?
| Needs Assessment | 2 | 2010 | 153 | 0.170 |
Why?
| Tertiary Healthcare | 1 | 2019 | 19 | 0.170 |
Why?
| Isoproterenol | 2 | 2012 | 52 | 0.170 |
Why?
| Bronchoconstriction | 1 | 2019 | 10 | 0.170 |
Why?
| Down-Regulation | 2 | 2012 | 388 | 0.170 |
Why?
| Population Groups | 1 | 2018 | 8 | 0.170 |
Why?
| Acetazolamide | 1 | 2018 | 20 | 0.160 |
Why?
| Pseudotumor Cerebri | 1 | 2018 | 24 | 0.160 |
Why?
| Drug Hypersensitivity | 1 | 2018 | 42 | 0.160 |
Why?
| Picornaviridae Infections | 1 | 2018 | 22 | 0.160 |
Why?
| Granulocytes | 1 | 2017 | 27 | 0.150 |
Why?
| Cells, Cultured | 5 | 2015 | 1737 | 0.150 |
Why?
| Signal Transduction | 2 | 2005 | 1751 | 0.150 |
Why?
| Epithelial Cells | 3 | 2019 | 255 | 0.150 |
Why?
| Prognosis | 5 | 2021 | 2126 | 0.150 |
Why?
| Particulate Matter | 1 | 2017 | 55 | 0.150 |
Why?
| Anticonvulsants | 1 | 2018 | 129 | 0.150 |
Why?
| Seasons | 1 | 2017 | 98 | 0.150 |
Why?
| Models, Biological | 2 | 2019 | 825 | 0.150 |
Why?
| Child Nutritional Physiological Phenomena | 1 | 2017 | 38 | 0.150 |
Why?
| Nut Hypersensitivity | 2 | 2015 | 3 | 0.150 |
Why?
| Proton Pump Inhibitors | 1 | 2017 | 84 | 0.140 |
Why?
| Primary Prevention | 1 | 2017 | 47 | 0.140 |
Why?
| Inflammation | 1 | 2021 | 679 | 0.140 |
Why?
| Respiratory Function Tests | 2 | 2008 | 98 | 0.140 |
Why?
| Evidence-Based Medicine | 1 | 2017 | 275 | 0.130 |
Why?
| Drugs, Chinese Herbal | 1 | 2015 | 11 | 0.130 |
Why?
| Basophil Degranulation Test | 1 | 2015 | 3 | 0.130 |
Why?
| Acetaminophen | 1 | 2019 | 350 | 0.130 |
Why?
| Therapies, Investigational | 1 | 2015 | 4 | 0.130 |
Why?
| Milk Proteins | 3 | 2024 | 77 | 0.130 |
Why?
| Delivery of Health Care | 1 | 2018 | 325 | 0.130 |
Why?
| Cell Differentiation | 3 | 2021 | 720 | 0.120 |
Why?
| Guideline Adherence | 2 | 2016 | 148 | 0.120 |
Why?
| Patient Compliance | 1 | 2016 | 247 | 0.120 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2018 | 580 | 0.120 |
Why?
| Advisory Committees | 1 | 2014 | 65 | 0.120 |
Why?
| Meningitis, Pneumococcal | 1 | 2013 | 6 | 0.120 |
Why?
| Interleukin-1 Receptor-Associated Kinases | 1 | 2013 | 11 | 0.120 |
Why?
| Mycobacterium fortuitum | 1 | 2013 | 6 | 0.110 |
Why?
| Macrolides | 1 | 2013 | 17 | 0.110 |
Why?
| Manikins | 1 | 2013 | 40 | 0.110 |
Why?
| Immunoglobulins, Intravenous | 1 | 2013 | 55 | 0.110 |
Why?
| Patient Selection | 1 | 2015 | 284 | 0.110 |
Why?
| Emergency Medicine | 1 | 2013 | 59 | 0.110 |
Why?
| Clarithromycin | 1 | 2013 | 40 | 0.110 |
Why?
| Sesamum | 1 | 2012 | 1 | 0.110 |
Why?
| Plant Extracts | 1 | 2015 | 192 | 0.110 |
Why?
| Pediatrics | 2 | 2013 | 324 | 0.110 |
Why?
| Cohort Studies | 4 | 2020 | 1547 | 0.110 |
Why?
| Methicillin | 1 | 2012 | 11 | 0.110 |
Why?
| Clindamycin | 1 | 2012 | 15 | 0.110 |
Why?
| Research | 1 | 2013 | 116 | 0.110 |
Why?
| Hypersensitivity, Immediate | 2 | 2018 | 13 | 0.100 |
Why?
| House Calls | 1 | 2012 | 28 | 0.100 |
Why?
| Chickens | 2 | 2021 | 118 | 0.100 |
Why?
| Medicaid | 2 | 2006 | 267 | 0.100 |
Why?
| Drug Resistance, Bacterial | 1 | 2012 | 81 | 0.100 |
Why?
| Telemedicine | 1 | 2018 | 457 | 0.100 |
Why?
| Cyclic AMP | 3 | 2012 | 106 | 0.100 |
Why?
| Morbidity | 1 | 2012 | 149 | 0.100 |
Why?
| Influenza Vaccines | 1 | 2011 | 42 | 0.100 |
Why?
| Protein Transport | 1 | 2012 | 195 | 0.100 |
Why?
| Gene Expression Profiling | 1 | 2016 | 1141 | 0.100 |
Why?
| Antibodies, Anti-Idiotypic | 1 | 2011 | 30 | 0.100 |
Why?
| Expert Testimony | 1 | 2010 | 13 | 0.100 |
Why?
| Powders | 2 | 2021 | 32 | 0.100 |
Why?
| Polymorphism, Genetic | 1 | 2012 | 193 | 0.100 |
Why?
| Food | 1 | 2010 | 68 | 0.090 |
Why?
| Child Nutrition Sciences | 1 | 2010 | 11 | 0.090 |
Why?
| Exercise | 1 | 2015 | 547 | 0.090 |
Why?
| Risk Assessment | 2 | 2017 | 1361 | 0.090 |
Why?
| Specialization | 1 | 2010 | 47 | 0.090 |
Why?
| Influenza, Human | 1 | 2011 | 120 | 0.090 |
Why?
| Clinical Protocols | 1 | 2010 | 122 | 0.090 |
Why?
| Maternal Exposure | 1 | 2010 | 87 | 0.090 |
Why?
| RNA, Ribosomal, 16S | 2 | 2023 | 116 | 0.090 |
Why?
| Retrospective Studies | 6 | 2016 | 6462 | 0.090 |
Why?
| Feces | 2 | 2023 | 136 | 0.090 |
Why?
| Algorithms | 2 | 2020 | 697 | 0.090 |
Why?
| Nutrition Surveys | 1 | 2010 | 122 | 0.090 |
Why?
| Cooking | 2 | 2020 | 19 | 0.090 |
Why?
| Caregivers | 1 | 2012 | 240 | 0.090 |
Why?
| Microarray Analysis | 1 | 2009 | 85 | 0.090 |
Why?
| Program Development | 1 | 2010 | 198 | 0.080 |
Why?
| Gene Expression | 2 | 2019 | 664 | 0.080 |
Why?
| Time Factors | 1 | 2016 | 3207 | 0.080 |
Why?
| Ovum | 2 | 2019 | 7 | 0.080 |
Why?
| Staphylococcal Infections | 1 | 2012 | 302 | 0.080 |
Why?
| Respiratory Mechanics | 1 | 2008 | 38 | 0.080 |
Why?
| Anti-Asthmatic Agents | 2 | 2006 | 31 | 0.080 |
Why?
| Program Evaluation | 1 | 2010 | 379 | 0.080 |
Why?
| Arachidonic Acid | 1 | 2008 | 39 | 0.080 |
Why?
| Docosahexaenoic Acids | 1 | 2008 | 29 | 0.080 |
Why?
| Staphylococcus aureus | 1 | 2012 | 363 | 0.080 |
Why?
| 2S Albumins, Plant | 2 | 2020 | 8 | 0.080 |
Why?
| Recurrence | 2 | 2010 | 692 | 0.080 |
Why?
| Statistics, Nonparametric | 1 | 2008 | 230 | 0.080 |
Why?
| Meta-Analysis as Topic | 1 | 2007 | 39 | 0.080 |
Why?
| Antibodies | 1 | 2008 | 178 | 0.080 |
Why?
| Health Surveys | 2 | 2012 | 261 | 0.080 |
Why?
| Luminescent Proteins | 2 | 2005 | 66 | 0.080 |
Why?
| Microscopy, Fluorescence | 1 | 2008 | 198 | 0.070 |
Why?
| Treatment Failure | 2 | 2020 | 141 | 0.070 |
Why?
| Health Status Indicators | 1 | 2007 | 94 | 0.070 |
Why?
| Agammaglobulinemia | 1 | 2006 | 10 | 0.070 |
Why?
| Genetic Diseases, X-Linked | 1 | 2006 | 10 | 0.070 |
Why?
| Infant, Newborn | 4 | 2019 | 2923 | 0.070 |
Why?
| Urban Health | 1 | 2006 | 36 | 0.070 |
Why?
| Infant Formula | 1 | 2008 | 152 | 0.070 |
Why?
| Acute Disease | 1 | 2007 | 403 | 0.070 |
Why?
| Consensus | 2 | 2017 | 156 | 0.070 |
Why?
| Nasal Polyps | 1 | 2006 | 9 | 0.070 |
Why?
| Anti-Bacterial Agents | 1 | 2012 | 825 | 0.070 |
Why?
| Amino Acids | 1 | 2008 | 369 | 0.070 |
Why?
| Bronchi | 1 | 2005 | 51 | 0.070 |
Why?
| Antibody Specificity | 2 | 2017 | 48 | 0.070 |
Why?
| Odds Ratio | 2 | 2019 | 600 | 0.070 |
Why?
| Adrenal Cortex Hormones | 1 | 2006 | 95 | 0.060 |
Why?
| Spine | 1 | 2006 | 112 | 0.060 |
Why?
| Pilot Projects | 1 | 2007 | 805 | 0.060 |
Why?
| Predictive Value of Tests | 2 | 2020 | 1044 | 0.060 |
Why?
| Societies, Scientific | 2 | 2017 | 15 | 0.060 |
Why?
| Albuterol | 2 | 2019 | 58 | 0.060 |
Why?
| Blood Proteins | 1 | 2004 | 100 | 0.060 |
Why?
| Osteoporosis | 1 | 2006 | 164 | 0.060 |
Why?
| Gene Transfer Techniques | 1 | 2003 | 41 | 0.060 |
Why?
| Tobacco Smoke Pollution | 1 | 2004 | 56 | 0.060 |
Why?
| Adenoviridae | 1 | 2003 | 58 | 0.060 |
Why?
| Cattle | 1 | 2024 | 224 | 0.060 |
Why?
| Green Fluorescent Proteins | 1 | 2003 | 110 | 0.060 |
Why?
| Sex Factors | 1 | 2006 | 766 | 0.060 |
Why?
| Butyrates | 1 | 2023 | 35 | 0.060 |
Why?
| Bone Density | 1 | 2006 | 416 | 0.060 |
Why?
| Genetic Vectors | 1 | 2003 | 139 | 0.060 |
Why?
| Receptors, Vasopressin | 1 | 2003 | 28 | 0.060 |
Why?
| Peak Expiratory Flow Rate | 1 | 2002 | 8 | 0.060 |
Why?
| Inhalation Spacers | 1 | 2002 | 8 | 0.060 |
Why?
| Antigens | 1 | 2023 | 53 | 0.060 |
Why?
| Food Additives | 1 | 2002 | 9 | 0.060 |
Why?
| Gelatin | 1 | 2002 | 26 | 0.060 |
Why?
| Immunoglobulin A | 1 | 2022 | 54 | 0.060 |
Why?
| Interleukin-2 | 1 | 2022 | 75 | 0.050 |
Why?
| Pituitary Gland | 1 | 2003 | 78 | 0.050 |
Why?
| Metabolome | 1 | 2023 | 108 | 0.050 |
Why?
| Fibroblasts | 1 | 2004 | 386 | 0.050 |
Why?
| Ovomucin | 1 | 2021 | 1 | 0.050 |
Why?
| Vitellogenins | 1 | 2021 | 2 | 0.050 |
Why?
| Ovalbumin | 1 | 2021 | 17 | 0.050 |
Why?
| Emollients | 1 | 2021 | 13 | 0.050 |
Why?
| Recombinant Proteins | 1 | 2003 | 570 | 0.050 |
Why?
| Socioeconomic Factors | 1 | 2004 | 638 | 0.050 |
Why?
| Hyperplasia | 1 | 2021 | 107 | 0.050 |
Why?
| Emergency Service, Hospital | 1 | 2006 | 540 | 0.050 |
Why?
| Pedigree | 1 | 2021 | 146 | 0.050 |
Why?
| Injections, Subcutaneous | 1 | 2020 | 58 | 0.050 |
Why?
| Lymphocyte Activation | 1 | 2021 | 197 | 0.050 |
Why?
| Peptides | 1 | 2021 | 276 | 0.050 |
Why?
| B-Lymphocytes | 1 | 2021 | 176 | 0.050 |
Why?
| Diet Therapy | 1 | 2019 | 9 | 0.050 |
Why?
| Phylogeny | 2 | 2016 | 269 | 0.050 |
Why?
| Milk | 2 | 2012 | 94 | 0.050 |
Why?
| Immunity | 1 | 2019 | 37 | 0.040 |
Why?
| Age of Onset | 2 | 2012 | 117 | 0.040 |
Why?
| Case-Control Studies | 1 | 2003 | 1229 | 0.040 |
Why?
| Tissue Array Analysis | 1 | 2019 | 50 | 0.040 |
Why?
| Egg Proteins, Dietary | 1 | 2018 | 2 | 0.040 |
Why?
| Kidney | 1 | 2004 | 821 | 0.040 |
Why?
| Muscle, Smooth | 1 | 2019 | 68 | 0.040 |
Why?
| Dose-Response Relationship, Immunologic | 1 | 2018 | 16 | 0.040 |
Why?
| Organ Culture Techniques | 1 | 2019 | 53 | 0.040 |
Why?
| Government Programs | 1 | 2018 | 19 | 0.040 |
Why?
| Gene Regulatory Networks | 1 | 2019 | 124 | 0.040 |
Why?
| Confidence Intervals | 1 | 2019 | 166 | 0.040 |
Why?
| ROC Curve | 1 | 2019 | 259 | 0.040 |
Why?
| Mice, Inbred Strains | 1 | 2019 | 199 | 0.040 |
Why?
| Extracellular Matrix | 1 | 2019 | 111 | 0.040 |
Why?
| Transforming Growth Factor beta | 1 | 2019 | 158 | 0.040 |
Why?
| Eating | 1 | 2019 | 163 | 0.040 |
Why?
| Rhinovirus | 1 | 2018 | 26 | 0.040 |
Why?
| Tertiary Care Centers | 1 | 2018 | 83 | 0.040 |
Why?
| Endoscopy | 1 | 2018 | 131 | 0.040 |
Why?
| Skin Irritancy Tests | 1 | 2017 | 3 | 0.040 |
Why?
| Gastrointestinal Diseases | 1 | 2018 | 135 | 0.040 |
Why?
| Multicenter Studies as Topic | 1 | 2017 | 91 | 0.040 |
Why?
| Blood Cells | 1 | 2017 | 58 | 0.040 |
Why?
| Specimen Handling | 1 | 2017 | 62 | 0.040 |
Why?
| Transcriptome | 1 | 2019 | 346 | 0.040 |
Why?
| Nutritional Sciences | 1 | 2017 | 26 | 0.040 |
Why?
| Community Health Services | 1 | 2018 | 114 | 0.040 |
Why?
| Molecular Sequence Annotation | 1 | 2016 | 31 | 0.040 |
Why?
| Staining and Labeling | 1 | 2017 | 106 | 0.040 |
Why?
| Quality Assurance, Health Care | 1 | 2018 | 164 | 0.040 |
Why?
| Histamine Antagonists | 1 | 2016 | 22 | 0.040 |
Why?
| Injections, Intramuscular | 1 | 2016 | 50 | 0.040 |
Why?
| Disease Progression | 1 | 2019 | 915 | 0.040 |
Why?
| Forkhead Transcription Factors | 1 | 2017 | 118 | 0.040 |
Why?
| Risk Reduction Behavior | 1 | 2017 | 69 | 0.040 |
Why?
| Eczema | 1 | 2017 | 25 | 0.040 |
Why?
| Models, Statistical | 1 | 2018 | 258 | 0.040 |
Why?
| Epigenesis, Genetic | 1 | 2019 | 399 | 0.030 |
Why?
| Interleukin-5 | 1 | 2015 | 6 | 0.030 |
Why?
| Quality Improvement | 1 | 2018 | 245 | 0.030 |
Why?
| DNA Methylation | 1 | 2019 | 575 | 0.030 |
Why?
| Risk | 1 | 2016 | 343 | 0.030 |
Why?
| Placebos | 1 | 2015 | 90 | 0.030 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2015 | 21 | 0.030 |
Why?
| Emergency Medical Services | 1 | 2016 | 126 | 0.030 |
Why?
| Cell Survival | 1 | 2017 | 657 | 0.030 |
Why?
| Dose-Response Relationship, Drug | 1 | 2019 | 1476 | 0.030 |
Why?
| Interleukin-10 | 1 | 2015 | 106 | 0.030 |
Why?
| Housing | 1 | 2014 | 48 | 0.030 |
Why?
| Flow Cytometry | 1 | 2017 | 547 | 0.030 |
Why?
| Medication Adherence | 1 | 2015 | 133 | 0.030 |
Why?
| Bacteria | 1 | 2016 | 257 | 0.030 |
Why?
| Emergency Treatment | 1 | 2013 | 33 | 0.030 |
Why?
| Amikacin | 1 | 2013 | 19 | 0.030 |
Why?
| Glycoproteins | 1 | 2013 | 132 | 0.030 |
Why?
| Antibiotic Prophylaxis | 1 | 2013 | 67 | 0.030 |
Why?
| Oxidative Stress | 1 | 2019 | 956 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2019 | 2002 | 0.030 |
Why?
| Azithromycin | 1 | 2013 | 42 | 0.030 |
Why?
| Antibody Affinity | 1 | 2012 | 11 | 0.030 |
Why?
| Urticaria | 1 | 2013 | 24 | 0.030 |
Why?
| Trees | 1 | 2012 | 19 | 0.030 |
Why?
| Eggs | 1 | 2012 | 10 | 0.030 |
Why?
| Comorbidity | 1 | 2015 | 666 | 0.030 |
Why?
| Poisson Distribution | 1 | 2012 | 32 | 0.030 |
Why?
| Incidence | 2 | 2006 | 1083 | 0.030 |
Why?
| Equipment Design | 1 | 2013 | 318 | 0.030 |
Why?
| Lysosomal-Associated Membrane Protein 1 | 1 | 2012 | 4 | 0.030 |
Why?
| Hospitals, University | 1 | 2012 | 89 | 0.030 |
Why?
| rab GTP-Binding Proteins | 1 | 2012 | 39 | 0.030 |
Why?
| Protein Isoforms | 1 | 2012 | 124 | 0.030 |
Why?
| Patient Care Team | 1 | 2013 | 273 | 0.030 |
Why?
| Rats | 2 | 2008 | 3417 | 0.020 |
Why?
| Food Labeling | 1 | 2011 | 6 | 0.020 |
Why?
| Regression Analysis | 1 | 2012 | 444 | 0.020 |
Why?
| HEK293 Cells | 1 | 2012 | 245 | 0.020 |
Why?
| Microbial Sensitivity Tests | 1 | 2012 | 290 | 0.020 |
Why?
| Membrane Proteins | 1 | 2013 | 389 | 0.020 |
Why?
| Hospitals, Pediatric | 1 | 2012 | 270 | 0.020 |
Why?
| Interleukin-4 | 1 | 2010 | 48 | 0.020 |
Why?
| Bronchitis | 1 | 2010 | 11 | 0.020 |
Why?
| Demography | 1 | 2010 | 103 | 0.020 |
Why?
| Diphenhydramine | 1 | 2009 | 20 | 0.020 |
Why?
| Self Efficacy | 1 | 2010 | 136 | 0.020 |
Why?
| Intestinal Mucosa | 1 | 2011 | 259 | 0.020 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2011 | 240 | 0.020 |
Why?
| Oscillometry | 1 | 2008 | 9 | 0.020 |
Why?
| Fluorescent Antibody Technique, Indirect | 1 | 2008 | 26 | 0.020 |
Why?
| Growth | 1 | 2008 | 43 | 0.020 |
Why?
| Infant Food | 1 | 2008 | 31 | 0.020 |
Why?
| Internet | 1 | 2010 | 275 | 0.020 |
Why?
| Computer Simulation | 1 | 2008 | 329 | 0.020 |
Why?
| Intubation, Intratracheal | 1 | 2008 | 129 | 0.020 |
Why?
| Diagnosis, Differential | 1 | 2010 | 1143 | 0.020 |
Why?
| Reference Standards | 1 | 2006 | 63 | 0.020 |
Why?
| Administration, Inhalation | 1 | 2006 | 119 | 0.020 |
Why?
| Drug Combinations | 1 | 2005 | 128 | 0.020 |
Why?
| Cause of Death | 1 | 2006 | 164 | 0.020 |
Why?
| Absorptiometry, Photon | 1 | 2006 | 173 | 0.020 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2005 | 170 | 0.020 |
Why?
| Recombinant Fusion Proteins | 1 | 2005 | 206 | 0.020 |
Why?
| Aged | 1 | 2018 | 10054 | 0.020 |
Why?
| Rats, Sprague-Dawley | 1 | 2008 | 1664 | 0.020 |
Why?
| Dietary Supplements | 1 | 2008 | 452 | 0.020 |
Why?
| Registries | 1 | 2006 | 552 | 0.010 |
Why?
| Sequence Homology | 1 | 2003 | 21 | 0.010 |
Why?
| Second Messenger Systems | 1 | 2003 | 19 | 0.010 |
Why?
| Phosphatidylinositols | 1 | 2003 | 25 | 0.010 |
Why?
| COS Cells | 1 | 2003 | 78 | 0.010 |
Why?
| Durable Medical Equipment | 1 | 2002 | 4 | 0.010 |
Why?
| Hydrophobic and Hydrophilic Interactions | 1 | 2003 | 42 | 0.010 |
Why?
| Pregnancy | 1 | 2010 | 2637 | 0.010 |
Why?
| Cloning, Molecular | 1 | 2003 | 197 | 0.010 |
Why?
| Reimbursement Mechanisms | 1 | 2002 | 25 | 0.010 |
Why?
| Insurance, Pharmaceutical Services | 1 | 2002 | 24 | 0.010 |
Why?
| Aging | 1 | 2008 | 782 | 0.010 |
Why?
| Base Sequence | 1 | 2003 | 719 | 0.010 |
Why?
| Pharmacies | 1 | 2002 | 63 | 0.010 |
Why?
| Bacterial Proteins | 1 | 2005 | 456 | 0.010 |
Why?
| Amino Acid Sequence | 1 | 2003 | 766 | 0.010 |
Why?
| Molecular Sequence Data | 1 | 2003 | 980 | 0.010 |
Why?
| Calcium | 1 | 2003 | 434 | 0.010 |
Why?
|
|
Jones's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|